Keybanc analyst Justin Patterson reiterated an Overweight rating for Meta Platforms META and raised the price forecast from $655 to $800 on Wednesday, citing strong second-quarter ad trends, stable macro conditions, and momentum in AI.Patterson increased his 2025 and 2026 revenue and earnings estimates for Meta, anticipating a better-than-expected performance driven by resilient ad spending, improving travel trends, and a weakening U.S. dollar. Also Read: Meta Has Gained 26% In 2025, Can The Rally Continue? ...

Shares of auto retail ecosystem companies have outperformed year-to-date, despite the announcement of auto tariffs and industry fundamentals weakening "even before the impact of tariffs have flowed through to vehicle pricing," according to JPMorgan.Analyst Rajat Gupta changed ratings on these four stocks.Cars.comJPMorgan upgraded the rating for Cars.com Inc CARS from Neutral to Overweight, while establishing a price target of $14.Shares of companies in the business-to-consumer)marketplaces have underperform ...

Core Viewpoint - Sarepta Therapeutics is experiencing a stock price increase following an update on the label expansion efforts for Elevidys, its gene therapy for Duchenne muscular dystrophy, despite the FDA's request for a black box warning regarding acute liver injury and failure [1][10]. Label Expansion and FDA Interaction - The FDA has requested a black box warning for Elevidys, which Sarepta agrees to, resolving material issues with the ambulant portion of the label [2][10]. - A Sarepta committee is reviewing cases of acute liver failure and is exploring enhanced immunosuppressive regimens for non-ambulant patients [3][4]. Financial Restructuring - Sarepta announced a strategic restructuring plan aimed at prioritizing programs and achieving approximately $400 million in annual cost reductions, with a workforce reduction of 36% impacting around 500 employees [5]. - The restructuring is projected to lower average annual non-GAAP R&D and SG&A expenses to between $800 million and $900 million starting in 2026 [5]. Financial Performance - Preliminary financial highlights for Q2 2025 show total net product revenue of $513 million, with Elevidys contributing $282 million [6]. - As of June 30, the company reported cash and investments of approximately $850 million [6]. Strategic Focus - The company is shifting its focus towards chronically administered therapies for neurodegenerative and pulmonary diseases, pausing several gene therapy programs for limb-girdle muscular dystrophy [7]. - Sarepta plans to submit a Biologics License Application for SRP-9003 for LGMD type 2E/R4 later this year [7]. Management Changes - In conjunction with the restructuring, Sarepta appointed Ian Estepan as President and Chief Operating Officer and Ryan Wong as CFO [9]. Analyst Insights - Analysts from William Blair suggest that the FDA's request for a black box warning indicates that complete removal of Elevidys from the market is unlikely, leading to increased investor confidence in the company's ability to manage long-term debts [10]. - There are expectations of short-term challenges for Elevidys as patients and doctors exhibit hesitation, with cautious investor sentiment until early results from the ENDEAVOR trial are available [10][11].

Group 1 - Tesla is launching a new six-seater, three-row version of the Model Y in China, which may resemble a minivan and is expected to help regain market share in the competitive Chinese EV market [1][2] - The Model Y L features increased length and height compared to the standard Model Y, providing more legroom for third-row passengers, which could attract families [3][4] - Tesla has not announced plans to release the Model Y L outside of China, despite strong demand anticipated among families [4][6] Group 2 - Tesla has been focusing on the profitability of electric vehicles and has not prioritized larger models like minivans, despite consumer demand for such vehicles [5][7] - The company recently unveiled the Robovan, which can seat up to 20 people and may enter production in 2026, indicating a potential shift towards larger vehicle offerings [6] - Tesla's stock is currently trading at $323.80, reflecting a 0.7% increase, but is down 15% year-to-date in 2025 [8]

The PNC Financial Services Group, Inc. PNC reported better-than-expected earnings for the second quarter on Wednesday.The company posted quarterly earnings of $3.85 per share which beat the analyst consensus estimate of $3.53 per share. The company reported quarterly sales of $5.661 billion which beat the analyst consensus estimate of $5.606 billion.PNC Financial Services said it sees FY 2025 revenue to up by 6% year over year.Bill Demchak, PNC Chairman and Chief Executive Officer said, “Our national growth ...

Goldman Sachs Group Inc. GS reported second-quarter results that beat analyst expectations on Wednesday, boosted by robust gains in its global banking and trading divisions.Net revenue rose 15% year over year to $14.58 billion, topping the consensus estimate of $13.36 billion, though it declined 3% from the prior quarter.GAAP earnings came in at $10.91 per share, up from $8.62 a year ago and above the $9.48 consensus. First-half EPS rose to $25.07 from $20.21 a year earlier.David Solomon, Chairman and CEO o ...

Johnson & Johnson JNJ posted better-than-expected quarterly earnings and raised its FY2025 earnings guidance on Wednesday.Johnson & Johnson reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68. The pharmaceutical giant reported sales of $23.74 billion, up 5.8% year over year and beating the consensus of $22.85 billion.Johnson & Johnson revised its fiscal year 2025 guidance. The company expects adjusted earnings of $10.80-$10.90, up fro ...

Interactive Brokers Group, Inc. IBKR will release earnings results for the second quarter, after the closing bell on Thursday, July 17.Analysts expect the Greenwich, Connecticut-based company to report quarterly earnings at 45 cents per share, up from 44 cents per share in the year-ago period. Interactive Brokers projects to report quarterly revenue at $1.37 billion, compared to $1.23 billion a year earlier, according to data from Benzinga Pro.On July 1, Interactive Brokers Group reported 3.448 million dail ...

There's little doubt that Nvidia NVDA is the stock of the decade so far, and as it hit a $4 trillion valuation, there remains plenty of optimism for further sustained growth. Nvidia was up 17.65% in the first half of 2025 amid challenging economic conditions for many Wall Street tech firms amid President Trump's bold strategy on reciprocal tariffs. However, the chipmaker has been buoyed by the gains made by its products in training leading artificial intelligence models, which has fueled global demand. This ...

At first glance, Advanced Micro Devices Inc. (NASDAQ: AMD) and Nvidia Corp. NVDA appear to belong in the same valuation range. Both trade in the 40x forward earnings range. But that's where the similarities end – and where the pricing disconnect begins.Margins Matter — And Nvidia's Are UntouchableNvidia isn't just growing – it's a profit machine. With 58% operating margins, 86% TTM revenue growth, and a balance sheet that boasts $43 billion in net cash, Nvidia runs like Apple Inc. AAPL but grows like a star ...